Learn more about whether Travere Therapeutics, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

If you are wondering whether Travere Therapeutics is still good value after its big rebound, you are not alone. This stock has quickly moved from recovery story to serious contender on many watchlists ...

Travere Therapeutics recently reached a new 52-week high after investors reacted to regulatory updates for its rare kidney disease therapy FILSPARI, including the removal of an FDA advisory committee ...

Travere Therapeutics (TVTX) just hit a fresh 52 week high after the FDA removed an advisory committee review and relaxed REMS monitoring for FILSPARI, sharpening focus on January’s FSGS approval ...

As of Wednesday, December 24, Travere Therapeutics, Inc.’s TVTX share price has surged by 17.75%, which has investors questioning if this is right time to sell.

The stock of commercial-stage biotech Travere Therapeutics (NASDAQ: TVTX) barreled into the late holiday period in style. On ...

Browse investing articles and stock analysis by Eric Volkman. Get expert financial insights and investment advice from The Motley Fool.

Travere Therapeutics Inc. has reached a significant milestone, with its stock hitting a 52-week high of 37.12 USD. This achievement underscores a remarkable year for the company, marked by a ...

Eric Dube, President and CEO, Travere Therapeutics: Yeah, I think there’s certainly an anticipation. I think we’re going to need to see, you know, the pricing there. We’re going to need to see what ...

Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations. Replays will be ...

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life ...